MediWound Ltd. Announces $30 Million Registered Direct Offering of Ordinary Shares Led by U.S. Mutual Fund
MediWound Ltd. has announced a $30 million registered direct offering of 1,734,105 ordinary shares at $17.30 per share, led by a U.S.-based mutual fund. The proceeds will primarily support pre-commercial activities for EscharEx, enhance manufacturing capabilities, and cover general corporate purposes. H.C. Wainwright & Co. is the exclusive placement agent for this offering.
MediWound Ltd. (Nasdaq: MDWD), a global leader in enzymatic therapeutics for tissue repair, has announced a $30 million registered direct offering of 1,734,105 ordinary shares at $17.30 per share. The offering is led by a prominent U.S.-based mutual fund along with other healthcare-focused investors. H.C. Wainwright & Co. is serving as the exclusive placement agent. MediWound plans to use the net proceeds primarily to support pre-commercial activities for EscharEx, enhance large-scale manufacturing capabilities, and for general corporate purposes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediWound Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536685-en) on September 29, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
